Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 4/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | C1R | P00736 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10581933 | 0.76 | AXL (0.39) | PARP1ACHEDHFR | |
| SCHEMBL2930063 | 0.74 | PARP1 (0.41) | PARP1ELANEACHE | |
| SCHEMBL7070701 | 0.69 | KMT2A (0.44) | PARP1ELANE | |
| SCHEMBL31140889 | 0.68 | PARP1 (0.46) | PARP1ELANEGRIN1GRIN2AACHE | |
| SCHEMBL7811084 | 0.68 | PARP1 (0.46) | PARP1ELANEGRIN1GRIN2AACHE | |
| SCHEMBL538144 | 0.68 | TDP1 (0.43) | PARP1ELANEACHE | |
| SCHEMBL3337344 | 0.67 | PARP1 (0.44) | PARP1ELANEGRIN1GRIN2AACHE | |
| SCHEMBL30013654 | 0.67 | PARP1 (0.44) | PARP1ELANEGRIN1GRIN2AACHE | |
| SCHEMBL10455684 | 0.67 | TDP1 (0.46) | PARP1ELANEGRIN1GRIN2AACHE | |
| SCHEMBL15058512 | 0.66 | KDM4E (0.44) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598159-B2 | Therapeutic pyrazoloquinoline derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-12-03 | — | — | US | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2166852-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | PARP1 4637/4885ELANE 4818/4885GRIN1 38/4885 |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | PARP1 4637/4885ELANE 4818/4885GRIN1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.